Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease-Reference-Cited by-同舟云学术

Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease

Published:2006-07-19 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Appleton Sarah¹,Jones Terry²,Poole Phillippa³,Lasserson Toby J⁴,Adams Robert⁵,Smith Brian J⁶,Muhammed Julia⁷

Affiliation:

1. Deptartment of Medicine; The Queen Elizabeth Hospital; Adelaide Australia

2. The Queen Elizabeth Hospital; Adelaide Australia

3. Department of Medicine; University of Auckland; Auckland New Zealand

4. Cochrane Editorial Unit; The Cochrane Collaboration; London UK

5. Department of Medicine; The Queen Elizabeth Hospital; Adelaide Australia

6. Department of Medicine, University of Adelaide; The Queen Elizabeth Hospital; Adelaide Australia

7. C/O Department of Medicine; University of Adelaide; Adelaide Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference67 articles.

1. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease;Dahl;American Journal of Respiratory & Critical Care Medicine,2001

2. Goodwin B Cox F Anderson W Wisniewski M Rickard K Comparison of salmeterol 42uG BID (SLG) versus ipratropium bromide 36 uG q.i.d. vs placebo on disease specific quality of life in COPD patients: reversible or non-reversible to ventolin American Thoracic Society International Conference 1999

3. Efficacy of salmeterol xinafoate in the treatment of COPD;Mahler;Chest,1999

4. A randomized, double-blind, double-dummy, comparative clinical trial of 12-week courses of salmeterol xinafoate versus ipratropium bromide versus placebo (prn ventolin®) in subjects with chronic obstructive pulmonary disease;http://ctr.gsk.co.uk,2005

5. Goodwin B Cox F Anderson W Wisniewski M Rickard K Comparison of salmeterol 42uG BID (SLG) versus ipratropium bromide 36 uG q.i.d. vs placebo on disease specific quality of life in COPD patients: reversible or non-reversible to ventolin American Thoracic Society International Conference 1999

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Up-to-date guidance towards improving medication adherence in patients with chronic obstructive pulmonary disease;Expert Review of Respiratory Medicine;2023-07-03

2. Conventional, Complementary and Alternative Medicines: Mechanistic Insights into Therapeutic Landscape of Chronic Obstructive Pulmonary Disease;International Journal of Chronic Obstructive Pulmonary Disease;2023-04

3. Pathophysiology, Therapeutic Targets, and Future Therapeutic Alternatives in COPD: Focus on the Importance of the Cholinergic System;Biomolecules;2023-03-05

4. The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis;Chronic Respiratory Disease;2023-01

5. COPD and glycopyrronium responsiveness assessment: An appraisal;Lung India;2023